A total of 153 patients with EGFR positive stage IIIb/IV NSCLC were enrolled and divided into the test group treated with EGFR-TKIs combined with traditional Chinese medicine and the control group treated with EGFR-TKIs alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.